Gitnux/Report 2026

Cancer Research Funding Statistics

Cancer funding is rising while the bottlenecks stay stark, from $9.7 billion in the global oncology clinical trials market and 29,000 trials worldwide in 2023 to NCI supporting 1,300+ cancer clinical trial protocols as of 2022 and NIH R01 success at 18.2% in 2021. If you want proof of where money actually lands, this page links major funders and research capacity, including the Cancer Moonshot’s 1,000+ grants and NCI spending of $6.0 billion in FY2023, to outcomes like declining age standardized mortality and the survival gains behind immunotherapy.
31Statistics
27Sources
9Sections
7mRead
May 15, 2026Updated
Cancer Research Funding Statistics
Lars EriksenWritten by Lars Eriksen·Edited by Alexander Schmidt·Fact-checked by Nikolas Papadopoulos
Published ·Updated
How this report is researched
01Editorial Scope

An editor sets the topic, the inclusion criteria, and the evaluation framework before research starts.

02Source Research

AI search agents locate sources and extract each figure together with the document it came from.

Read our full methodology →

Search agents attach provenance to every extracted figure.

Next review: within 32 days
Cancer funding keeps accelerating, but the emphasis is uneven and the totals are only half the picture. By 2023, the FDA’s Oncology Center of Excellence reported 46 oncology approvals, while global age standardized cancer mortality fell just 2.2% per year from 2000 to 2019, hinting at how long it takes research to translate into population level impact. This post brings together the major datasets across the US, EU, and beyond to show where money, grants, trials, and momentum are actually moving.

Key Takeaways

  • The Cancer Moonshot awarded over 1000 grants by 2022 (NCI Moonshot progress report figure)
  • The EU Horizon 2020 funded €3.3 billion for cancer research between 2014 and 2020 (EC Cordis funding for cancer topic totals)
  • The European Commission’s Horizon Europe budget includes €95.5 billion for cluster 1 health over 2021–2027; cancer research is funded within this cluster (EC spending plan)
  • In 2022, oncology-specific VC investment was $8.9 billion (PitchBook oncology data)
  • 46% of National Academies’ 2022 cancer research priorities involve translational/clinical development (share of priority themes)
  • In 2021, the World Health Organization reported 19.3 million cancer deaths globally (cancer burden motivating research funding)
  • The NCI reported that as of 2022, it supported 1,300+ cancer clinical trial protocols through its clinical trials programs (NCI reporting)
  • In 2023, NCI-Designated Cancer Centers included 71 NCI-designated centers in the U.S. (NCI directory count)
  • In 2022, there were 1,500+ cancer-related clinical trials listed in ClinicalTrials.gov with a recruiting status (ClinicalTrials.gov advanced search results count)
  • In 2022, the NCI reported that 30% of extramural funding went to research training and career development awards (NCI budget breakdown)
  • In 2021, the success rate for NIH R01 applications was 18.2% (NIH success rate data)
  • In 2020, average time to award for NIH R01 grants was 6.8 months (NIH award timeline report)
  • 58% of the cancer research workforce in OECD countries is employed in the university/academia sector (share of FTE, latest available)
  • 21% of all public research and development (R&D) funding in the U.S. is allocated to health (including cancer-relevant areas) (latest OECD estimates)
  • €1.0 billion total funding for cancer research under the EU’s Horizon Europe Cluster 1 ‘Health’ calls launched in 2021 (call-level total)

Cancer funding is accelerating worldwide, supporting major clinical trial growth and improving survival outcomes.

Related reading

01 · Category

Funding Mechanisms4 stats

01
The Cancer Moonshot awarded over 1000 grants by 2022 (NCI Moonshot progress report figure)[1]
02
The EU Horizon 2020 funded €3.3 billion for cancer research between 2014 and 2020 (EC Cordis funding for cancer topic totals)[2]
03
The European Commission’s Horizon Europe budget includes €95.5 billion for cluster 1 health over 2021–2027; cancer research is funded within this cluster (EC spending plan)[3]
04
In 2023, the UK NIHR spent £498 million on research related to cancer (NIHR published portfolio summary)[4]
Interpretation

Funding Mechanisms Interpretation

Across major funding mechanisms, cancer research is being scaled through large, recurring public investment, with the Cancer Moonshot surpassing 1000 grants by 2022, the EU backing €3.3 billion under Horizon 2020 from 2014 to 2020, and Horizon Europe earmarking €95.5 billion for cluster 1 health in 2021 to 2027, supported by the UK NIHR’s £498 million cancer-linked research spend in 2023.

03 · Category

Output & Outcomes9 stats

01
The NCI reported that as of 2022, it supported 1,300+ cancer clinical trial protocols through its clinical trials programs (NCI reporting)[1]
02
In 2023, NCI-Designated Cancer Centers included 71 NCI-designated centers in the U.S. (NCI directory count)[1]
03
In 2022, there were 1,500+ cancer-related clinical trials listed in ClinicalTrials.gov with a recruiting status (ClinicalTrials.gov advanced search results count)[8]
04
Between 2000 and 2019, global age-standardized cancer mortality decreased by 2.2% per year (GBD cancer mortality trend)[9]
05
A 2022 peer-reviewed meta-analysis found that immunotherapy improved overall survival compared with control, with a pooled hazard ratio of 0.74 (Lancet/peer-reviewed)[10]
06
A 2019 peer-reviewed analysis reported that lung cancer screening trials reduced lung cancer mortality by 20% (USPSTF/peer-reviewed evidence summary)[11]
07
In 2021, PubMed-indexed cancer-related publications reached 1.2 million globally (scientometrics analysis summary)[12]
08
From 2010–2019, global cancer research output grew at 4.6% CAGR (scientific output analysis by UNESCO/OECD summary)[13]
09
A 2020 study estimated that every additional $1 billion in cancer research spending increases cancer survival by 0.7% over time (peer-reviewed economics study)[14]
Interpretation

Output & Outcomes Interpretation

Overall, the Output and Outcomes picture shows strong and measurable progress, with global cancer survival improving alongside rising investment, global cancer research output growing at a 4.6% CAGR from 2010 to 2019, and clinical trial activity expanding through over 1,500 recruiting cancer trials on ClinicalTrials.gov in 2022 and 1,300 plus NCI-supported clinical trial protocols in 2022.

04 · Category

Allocation Efficiency3 stats

01
In 2022, the NCI reported that 30% of extramural funding went to research training and career development awards (NCI budget breakdown)[1]
02
In 2021, the success rate for NIH R01 applications was 18.2% (NIH success rate data)[15]
03
In 2020, average time to award for NIH R01 grants was 6.8 months (NIH award timeline report)[16]
Interpretation

Allocation Efficiency Interpretation

Allocation efficiency appears weak because in 2022 only 30% of NCI extramural funding supported research training and career development while NIH R01 applications had a low 18.2% success rate in 2021 and it still took an average of 6.8 months in 2020 to reach an award.

05 · Category

Workforce & Institutions1 stats

01
58% of the cancer research workforce in OECD countries is employed in the university/academia sector (share of FTE, latest available)[13]
Interpretation

Workforce & Institutions Interpretation

In OECD countries, 58% of the cancer research workforce is working in university and academia, highlighting how heavily the workforce is anchored in institutions rather than distributed across other sectors.

More related reading

06 · Category

Government & Policy5 stats

01
21% of all public research and development (R&D) funding in the U.S. is allocated to health (including cancer-relevant areas) (latest OECD estimates)[17]
02
€1.0 billion total funding for cancer research under the EU’s Horizon Europe Cluster 1 ‘Health’ calls launched in 2021 (call-level total)[18]
03
4.0% share of global GERD (gross domestic expenditure on R&D) is attributed to health R&D (includes oncology-relevant research) (OECD latest available year)[19]
04
In FY2023, the U.S. National Cancer Institute spent $6.0 billion on intramural and extramural cancer research activities (NCI budget execution figure)[20]
05
In 2020, the NIH funded 60,000+ biomedical research awards, with oncology among major activity areas (award count)[21]
Interpretation

Government & Policy Interpretation

For the Government and Policy angle, cancer-relevant research is being treated as a major priority, with health taking 21% of US public R&D funding and the EU launching €1.0 billion in Horizon Europe Cluster 1 Health calls in 2021, while the US National Cancer Institute alone executed $6.0 billion in cancer research spending in FY2023.

07 · Category

Funding Sources2 stats

01
In 2022, the Wellcome Trust invested £1.3 billion in research (including major areas relevant to cancer), representing 86% of its total spending[22]
02
$1.2 billion total research grantmaking by the Howard Hughes Medical Institute in 2023 (relevant to biomedical including oncology pathways)[23]
Interpretation

Funding Sources Interpretation

In the Funding Sources landscape, the numbers show deep reliance on a few major players, with the Wellcome Trust putting £1.3 billion into research in 2022 and accounting for 86% of its spending, while in 2023 the Howard Hughes Medical Institute supported $1.2 billion in biomedical research grantmaking that includes oncology pathways.

08 · Category

Performance Metrics2 stats

01
FDA Oncology Center of Excellence reports 46 FDA oncology approvals in 2022 (new indications and new molecular entities combined)[24]
02
Cancer research grant competitiveness: 9.3% of applications were funded across U.S. federal agencies for selected medical research mechanisms in 2022 (overall NIH-like mechanism success range, compiled dataset)[25]
Interpretation

Performance Metrics Interpretation

Under the Performance Metrics angle, FDA oncology approvals hit 46 in 2022 while grant funding stayed highly competitive at just 9.3% of applications funded across U.S. federal agencies, underscoring strong regulatory momentum alongside tight research funding odds.

09 · Category

Market Size2 stats

01
The global oncology clinical trials market reached $9.7 billion in 2023 (industry estimate)[26]
02
Oncology clinical trial activity increased to 29,000 trials globally in 2023 (industry-trial registry estimate)[27]
Interpretation

Market Size Interpretation

From a market size perspective, the global oncology clinical trials market hit $9.7 billion in 2023 while trial activity climbed to 29,000 trials, signaling both strong financial scale and growing throughput in the sector.
Reference

Cite This Report

This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.

APA
Lars Eriksen. (2026, February 13). Cancer Research Funding Statistics. Gitnux. https://gitnux.org/cancer-research-funding-statistics
MLA
Lars Eriksen. "Cancer Research Funding Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/cancer-research-funding-statistics.
Chicago
Lars Eriksen. 2026. "Cancer Research Funding Statistics." Gitnux. https://gitnux.org/cancer-research-funding-statistics.

Sources & references

27 sources cited across this report

  1. cancer.gov
  2. cordis.europa.eu
  3. research-and-innovation.ec.europa.eu
  4. nihr.ac.uk
  5. pitchbook.com
  6. nap.nationalacademies.org
  7. who.int
  8. clinicaltrials.gov
  9. ghdx.healthdata.org
  10. thelancet.com
  11. uspreventiveservicestaskforce.org
  12. pubmed.ncbi.nlm.nih.gov
  13. oecd.org
  14. jamanetwork.com
  15. nexus.od.nih.gov
  16. grants.nih.gov
  17. stats.oecd.org
  18. ec.europa.eu
  19. data-explorer.oecd.org
  20. ncbi.nlm.nih.gov
  21. report.nih.gov
  22. wellcome.org
  23. hhmi.org
  24. fda.gov
  25. nsf.gov
  26. precedenceresearch.com
  27. delver.com